Evidence map›Paper›PMID 39580805›Full record

ArticleCell reports2024

High-affinity agonists reveal recognition motifs for the MRGPRD GPCR.

Chunyu Wang, Yongfeng Liu, Marion Lanier, Adam Yeager, Isha Singh, Ryan H Gumpper, Brian E Krumm, Chelsea DeLeon, Shicheng Zhang, Marcus Boehm and 9 more

Abstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chunyu WangKey Laboratory of Immune Response and Immunotherapy, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Insitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, China.
Yongfeng LiuDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Marion LanierEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Adam YeagerEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Isha SinghDepartment of Pharmaceutical Sciences, University of California, San Francisco, School of Medicine, San Francisco, CA, USA.
Ryan H GumpperDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Brian E KrummDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Chelsea DeLeonDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Shicheng ZhangDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Marcus BoehmEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Richard PittnerEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Alain BaronEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Lisa DvorakEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Corinne BaconEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA.
Brian K ShoichetDepartment of Pharmaceutical Sciences, University of California, San Francisco, School of Medicine, San Francisco, CA, USA.
Esther MartinboroughEscient Pharmaceuticals, 10578 Science Center Drive, Suite 250, San Diego, CA 92121, USA. Electronic address: emartinborough@escientpharma.com.
Jonathan F FayDepartment of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: jfay@som.umaryland.edu.
Can CaoKey Laboratory of Immune Response and Immunotherapy, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Insitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, China. Electronic address: caocan23@ustc.edu.cn.
Bryan L RothDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Division of Chemical Biology and Medicinal Chemistry, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: bryan_roth@med.unc.edu.

Funding

Illuminating the Druggable GPCR-omeU24DK116195 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2017 to 2022
$14.3M
Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
STRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORSR01DA055656 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2022 to 2026
$2.8M
NIDA NIH HHS R01 DA055656NIDDK NIH HHS U24 DK116195NIGMS NIH HHS R35 GM122481
6 · The paper itself

Abstract

The human MRGPRD protein is a member of the Mas-related G protein-coupled receptors (MRGPRs) that is involved in the sensing of pain, itch, and other inflammatory stimuli. As with other MRGPRs, MRGPRD is a relatively understudied receptor with few known agonists. The most potent small-molecule agonist of MRGPRD reported so far is β-alanine, with an affinity in the micromole range, which largely restricts its functional study. Here, we report two MRGPRD agonists, EP-2825 and EP-3945, that are approximately 100-fold more potent than β-alanine and determine the structures of MRGPRD-Gq in complex with EP-2825 and EP-3945, respectively. The structures reveal distinct agonist binding modes of MRGPRD and large conformational plasticity of the orthosteric pocket. Collectively, the discovery of high-affinity MRGPRD agonists and their distinct binding modes will facilitate the functional study and the structure-based design of ligands targeting this understudied receptor.

Indexed as

Receptors, G-Protein-CoupledAmino Acid MotifsBinding SitesHEK293 CellsHumansProtein BindingReceptors, G-Protein-Coupledagonist recognitionCP: Molecular biologydrug discoveryGPCRMRGPRDstructure

Identifiers

PMID39580805
PMCPMC12006980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.